Secretory phospholipase A2 inhibitors and calmodulin antagonists as inhibitors of cytosolic phospholipase A2.
Human cytosolic phospholipase A2 (cPLA2, 85 kDa) appears to be pharmacologically distinct from human secretory phospholipase A2 (sPLA2, 14 kDa). Marine natural products and PLA2 substrate and product analogs were potent inhibitors of human recombinant sPLA2 (r-sPLA2), whereas these compounds stimulated, weakly inhibited, or had no effect on cPLA2 activity from the human monocytic cell line U937. In contrast, within a series of seven reported calmodulin (CaM) antagonists tested, significant correlations among the rank order of potencies of these compounds as inhibitors of cPLA2, r-sPLA2, and a CaM-dependent phosphodiesterase were observed. The correlated inhibitory effects of the hydrophobic CaM antagonists on cPLA2 and sPLA2 may reflect a common feature (possibly a hydrophobic domain) shared by these two types of enzymes.
Hope
W C
WC
Department of Bronchopulmonary Research, Hoffmann-La Roche Inc., Nutley, NJ 07110.
Chen
T
T
Morgan
D W
DW
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000818:Animals; D002147:Calmodulin / Q000037:antagonists & inhibitors*; D002460:Cell Line; D003600:Cytosol / Q000201:enzymology*; D006801:Humans; D051379:Mice; D009000:Monocytes / Q000187:drug effects / Q000201:enzymology; D010741:Phospholipases A / Q000037:antagonists & inhibitors* / Q000378:metabolism; D054467:Phospholipases A2; D011994:Recombinant Proteins
D002147:Calmodulin; D011994:Recombinant Proteins; D010741:Phospholipases A; D054467:Phospholipases A2; D015105:3',5'-Cyclic-AMP Phosphodiesterases